Abstract 4139873: Isolated Tricuspid Replacement versus Repair among Medicare Beneficiaries
Background: Evidence is limited regarding mid-term outcomes following isolated tricuspid operations for tricuspid regurgitation at the population level. Objective: This study aimed to compare the mid-term outcomes following isolated tricuspid valve replacement versus repair using contemporary data. Methods: We analyzed the national data on Medicare beneficiaries aged ≥65 who underwent isolated tricuspid valve replacement or repair between January 2016 and December 2020. The primary outcome was mid-term (up to 3 years) all-cause mortality. The secondary outcomes included mid-term major adverse cardiovascular events (MACE) and heart failure hospitalizations, as well as in-hospital permanent pacemaker implantation rates. MACE comprised all-cause mortality, heart failure hospitalization, stroke, and tricuspid reoperations. A propensity score-matching analysis was conducted to compare the two groups. Results: A total of 1,693 patients were included (replacement= 655 patients, repair= 1,038 patients). In the matched cohort (597 patients in each group), the overall mortality and MACE were 40% and 47% at 3 years, respectively. Tricuspid valve replacement was associated with similar all-cause mortality in comparison to repair (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.95-1.39; P=0.15). Similarly, the rates of MACE and heart failure hospitalizations were similar (adjusted HR, 1.10; 95% CI, 0.93-1.32, P=0.27; subdistribution HR, 1.07, 95% CI, 0.75-1.54, P=0.69, respectively) between these two procedures. Patients undergoing replacement required permanent pacemaker implantations more frequently (25.4% vs. 12.4%; P<0.001). Conclusions: Isolated surgical tricuspid valve replacement was associated with similar clinical outcomes compared to repair, except for permanent pacemaker implantation rates. The overall high mid-term mortality and morbidity with either treatment highlight the need for better options and further research to optimize the indication and timing of intervention.
Authors
- Tsuyoshi Kaneko (ORCID: https://orcid.org/0000-0001-6500-7471)
- Yusuke Tsugawa (ORCID: https://orcid.org/0000-0002-1937-4833)
- Hiroshi Gotanda (ORCID: https://orcid.org/0000-0003-4238-0171)
- Tomonari Shimoda (ORCID: https://orcid.org/0000-0001-5092-3127)
- Sammy Elmariah (ORCID: https://orcid.org/0000-0002-8013-8733)
- Hiroki Ueyama (ORCID: https://orcid.org/0000-0003-4812-7193)
- Shinichi Fukuhara (ORCID: https://orcid.org/0000-0002-7898-5159)
- Atsuyuki Watanabe (ORCID: https://orcid.org/0000-0001-8781-0329)
- Toshiki Kuno (ORCID: https://orcid.org/0000-0002-2487-8366)
- Yujiro Yokoyama (ORCID: https://orcid.org/0000-0001-8552-9496)
- Yoshihisa Miyamoto (ORCID: https://orcid.org/0000-0003-2680-7665)
Institutions
- Cedars-Sinai Medical Center (US)
- Mount Sinai Hospital (US)
- Emory University (US)
- University of California, Los Angeles (US)
- Washington University in St. Louis (US)
- University of Michigan (US)
- Massachusetts General Hospital (US)
- Michigan United (US)
- University of Tsukuba Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Circulation
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1161/circ.150.suppl_1.4139873
- Primary Topic
- Biomedical Ethics and Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00